The demonstration that progranulin knockdown sensitizes CRC cells to cytotoxic agents is in line with previous reports associating increased levels of progranulin with chemoresistance and a worse prognosis in hepatocellular carcinoma (Cheung et al., 2011; Wong et al., 2014), breast cancer (Abrhale et al., 2011; Kim and Serrero, 2006), multiple myeloma (Wang et al., 2006), and ovarian cancer (Pizarro et al., 2007). Here, GRN is linked to breast cancer.